IB
Immatics Biotechnologies
Germany - Munich
BiotechnologyFocus: Personalized T-cell Directed Immunotherapies
Immatics Biotechnologies is a life sciences company focused on Personalized T-cell Directed Immunotherapies.
Oncology
Open Jobs
4
Pipeline & Clinical Trials
APVAC1 vaccine plus Poly-ICLC and GM-CSF
GlioblastomaClinical Trials (1)
NCT02149225GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients
Phase 1glioblastoma multiforme multipeptide vaccine IMA950
Brain and Central Nervous System TumorsClinical Trials (1)
NCT01222221Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase 1IMA401
Refractory CancerClinical Trials (1)
NCT05359445IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor
Phase 1Cyclophosphamide
GlioblastomaClinical Trials (1)
NCT01403285Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma
Phase 1IMA402
Refractory CancerClinical Trials (1)
NCT05958121IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors
Phase 1/2IMA970A plus CV8102 and Cyclophosphamide
Hepatocellular CarcinomaClinical Trials (1)
NCT03203005IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients
Phase 1/2Endoxana, Leukine, IMA910
Colorectal CarcinomaClinical Trials (1)
NCT00785122IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy (IMA910-101)
Phase 1/2IMA 950
CNS Tumor, AdultClinical Trials (1)
NCT01920191Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma
Phase 1/2Arm A: F16IL2 in combination with paclitaxel
Merkel Cell CarcinomaClinical Trials (1)
NCT02054884F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma
Phase 2Endoxana, IMA901, Leukine
Renal Cell CarcinomaClinical Trials (1)
NCT00523159IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease
Phase 2Sunitinib
Metastatic Renal Cell CarcinomaClinical Trials (1)
NCT01265901IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
Phase 3Open Jobs (4)
Interview Prep Quick Facts
Portfolio: 11 clinical trials
Top TAs: Oncology
Open Roles: 4 active jobs
Hiring Trend
Stable
4
Open Roles
+2
Added
-0
Filled/Removed
Based on last 4 crawl cycles